Breakthrough ALS Drug

Two undergraduates from Brown University, Josh and Justin, identified a gap in ALS treatment and founded a company called Amylix to develop a drug aimed at protecting nerve cells under attack. Their innovative approach combines a naturally occurring substance with a prescription drug for a rare metabolic disorder, marking a significant step forward in tackling serious neurodegenerative diseases.